Skip to main content
35 search results for:

Nab-paclitaxel 

sort by |
"newest" sorts results by publication date. "most relevant" also considers factors like how often the search phrase is in the result.
  1. 27-05-2022 | Breast cancer | News | Article

    Neoadjuvant denosumab does not boost nab-paclitaxel response

    They observed no significant QoL differences between the two denosumab arms but found that patients receiving nab-paclitaxel weekly reported significantly worse mean scores for physical and functional well-being, additional concerns, and FACT-Taxane total score than those receiving nab-paclitaxel on days 1 and 8 every 3 weeks.

  2. 17-05-2021 | Non-small-cell lung cancer | News | Article

    Nab-paclitaxel offers alternative to docetaxel in pretreated advanced NSCLC

    Nab-paclitaxel offers a similar survival benefit to docetaxel when given to previously treated patients with advanced non-small-cell lung cancer, show data from the phase 3 J-AXEL trial.

  3. 14-10-2022 | Non-small-cell lung cancer | News | Article

    CHOICE-01 shows survival benefit of adding toripalimab to chemo in advanced NSCLC

    The CHOICE-01 trial enrolled 465 individuals with treatment-naïve locally advanced or metastatic NSCLC lacking EGFR or ALK alterations and randomly assigned them to receive intravenous toripalimab 240 mg or placebo every 3 weeks alongside four to six cycles of chemotherapy, consisting of nab-paclitaxel plus carboplatin for squamous disease and pemetrexed plus cisplatin or carboplatin for nonsquamous disease.

  4. 17-03-2022 | Triple-negative breast cancer | News | Article

    NeoTRIP: No pCR benefit from atezolizumab–chemotherapy in TNBC patients

    The addition of atezolizumab to neoadjuvant carboplatin and nab-paclitaxel does not significantly increase the rate of pathologic complete response among women undergoing surgery for treatment-naïve triple-negative breast cancer, research suggests.

  5. 06-06-2022 | ASCO 2022 | Conference coverage | Article

    DESTINY-Breast04 ‘practice changing’ for HER2-low metastatic breast cancer

    The primary endpoint was independently assessed progression-free survival (PFS) in the hormone receptor-positive population, and this was significantly longer for the 331 participants who were randomly assigned to receive T-DXd 5.4 mg/kg every 3 weeks than for their 163 counterparts who instead received physician’s choice of capecitabine, eribulin, gemcitabine, paclitaxel, or nab-paclitaxel.

  6. 24-05-2022 | Breast cancer | News | Article
    News in brief

    No benefit of etirinotecan pegol for breast cancer patients with brain metastases

    Median OS was 7.8 months for the 92 patients with pretreated, nonprogressive brain metastases who were randomly assigned to receive etirinotecan pegol 145 mg/m 2 every 21 days and a comparable 7.5 months for their 86 counterparts instead given physicians’ choice of single-agent eribulin, ixabepilone, vinorelbine, gemcitabine, paclitaxel, docetaxel, or nab-paclitaxel.

  7. 06-04-2021 | Non-small-cell lung cancer | News | Article

    Tislelizumab addition boosts advanced squamous NSCLC outcomes

    The team speculates that the increased rate in the nab-paclitaxel group “may be because of more frequent administration and safety assessments with nab-paclitaxel (once weekly) compared with paclitaxel (every 3 weeks).”

  8. 10-06-2021 | ASCO 2021 | Conference coverage | Article

    Long-term benefits to neoadjuvant durvalumab in triple-negative breast cancer

    After this, both groups received additional nab-paclitaxel 125 mg/m² weekly for 12 weeks then epirubicin 90 mg/m 2 and cyclophosphamide 600 mg/m 2 every 2 weeks for 4 cycles.

  9. play
    01-10-2020 | ESMO 2020 | Conference coverage | Video

    IMpassion130 and IMpassion131: The difference a taxane makes?

    Leisha Emens summarizes their IMpassion130 trial of atezolizumab and nab-paclitaxel in patients with advanced triple-negative breast cancer, and comments on the differences with the IMpassion131 study that instead used paclitaxel.

  10. 22-12-2020 | SABCS 2020 | Conference coverage | Article

    ​​​​​​​TNBC patients benefit from pembrolizumab in combination with various chemotherapies

    Similarly, pembrolizumab was associated with a significant improvement in median PFS among patients with a CPS of 1 or more who received nab-paclitaxel or paclitaxel, at 6.3 versus 5.3 months and 9.4 versus 3.8 months, respectively (HRs=0.66 and 0.46).

  11. 20-09-2020 | ESMO 2020 | Conference coverage | Article

    IMpassion130: ‘Clinically meaningful’ OS boost with atezolizumab in PD-L1-positive advanced TNBC

    The final overall survival results of the IMpassion130 trial continue to support the first-line use of atezolizumab plus nab-paclitaxel in PD-L1-expressing patients with metastatic triple-negative breast cancer.

  12. 19-11-2020 | FDA | News | Article
    approvalsWatch

    FDA approves pembrolizumab for PD-L1-expressing advanced TNBC

    The recommended pembrolizumab dose  is 200 mg every 3 weeks or 400 mg every 6 weeks before chemotherapy consisting of nab-paclitaxel, paclitaxel, or gemcitabine plus carboplatin.

  13. 18-09-2020 | FDA | News | Article
    Regulatory update

    FDA issues alert on atezolizumab–paclitaxel duo in breast cancer

    The PD-L1 inhibitor given in combination with nab-paclitaxel is currently approved for metastatic TNBC patients with PD-L1-positive disease, and the FDA stresses that healthcare providers should not replace nab-paclitaxel with paclitaxel for this indication.

  14. 23-09-2020 | ESMO 2020 | Conference coverage | Article

    IMpassion131 rules out atezolizumab–paclitaxel duo in metastatic TNBC

    Adding atezolizumab to paclitaxel does not improve progression-free survival or overall survival in patients with unresectable locally advanced or metastatic triple-negative breast cancer, IMpassion131 data show.

  15. 28-09-2020 | ESMO 2020 | Conference coverage | Article

    Neoadjuvant atezolizumab–chemotherapy improves TNBC pathologic response

    Nadia Harbeck explains why the IMpassion031 results cement the role of neoadjuvant immunotherapy plus chemotherapy in early-stage triple-negative breast cancer (2:54) Harbeck video In the double-blind study, 333 patients with early-stage TNBC (primary tumor >2 cm) were randomly assigned to receive a 12-week course of neoadjuvant atezolizumab 840 mg or placebo every 2 weeks alongside weekly nab-paclitaxel 125 mg/m 2 .

  16. 05-12-2019 | Non-small-cell lung cancer | News | Article

    Adding pembrolizumab to chemotherapy boosts HRQoL in metastatic NSCLC

    Previously untreated patients with stage IV squamous non-small-cell lung cancer report an improved health-related quality of life if carboplatin plus paclitaxel or nab-paclitaxel is supplemented with pembrolizumab, KEYNOTE-407 study results suggest.

  17. 13-09-2019 | Non-small-cell lung cancer | News | Article

    IMpower131: Strongly PD-L1-positive NSCLC patients may benefit from atezolizumab–chemotherapy

    The final analysis of the IMpower131 trial reveals an overall survival benefit with the addition of atezolizumab to carboplatin and nab-paclitaxel chemotherapy for treatment-naïve patients with stage IV squamous non-small-cell lung cancer who strongly express PD-L1.

  18. 10-02-2020 | Guidelines | News | Article
    guidelinesWatch        

    ASCO/Ontario Health update released for stage IV NSCLC without driver alterations

    For patients with squamous cell carcinoma, a high PD-L1 expression, and a PS of 0–1, the recommendations in order of preference are: Single-agent pembrolizumab; Pembrolizumab, carboplatin, and paclitaxel or nab-paclitaxel.

  19. 21-01-2020 | Non-small-cell lung cancer | News | Article

    Age no bar for treatment selection in older NSCLC patients

    Weiss et al caution that these findings are “not definitive due to the nonrandomized nature of the data,” but point to “the promising efficacy of nab-paclitaxel in older patients with lung cancer.”

  20. 06-12-2019 | FDA | News | Article
    approvalsWatch

    FDA approves atezolizumab combination for metastatic NSCLC

    medwireNews : US patients with stage IV, nonsquamous non-small-cell lung cancer (NSCLC) lacking EGFR or ALK alterations can now receive first-line treatment with atezolizumab plus nab-paclitaxel and carboplatin.

Filter search results

Search Operators:

„ ... ... “ Finds documents with exactly this word group, in exactly this word order and spelling (e.g., "employer branding").
AND Finds documents with both search terms (e.g., sales AND bonus).
OR Finds documents with one or the other search term (e.g., porsche OR volkswagen).
Blank Space Finds documents with all search terms. Blank space is understood as AND (e.g., man robot production).
NOT Finds documents with no appearance of the word behind NOT (e.g., ford NOT "harrison ford").
COUNT(...)>n Finds documents where the search term is mentioned at least "n" times."n" may be any number (e.g., COUNT(gear)>8).
NEAR(..., ..., ) Finds documents with both search terms in any word order, permitting "n" words as a maximum distance between them. Best choose between 15 and 30 (e.g., NEAR(recruit, professionals, 20)).
* Finds documents with the search term in word versions or composites. The star * marks whether you wish them BEFORE, BEHIND, or BEFORE and BEHIND the search term (e.g., lightweight*, *lightweight, *lightweight*).
? Finds documents with the search termn in different spellings."?" allows only one character (e.g., organi?ation).
& + - Special characters are understood as AND (e.g., Miller Bros. & Sons).

You can use operators in your search query to narrow down your results even more.

Tap the operator, or hover the mouse pointer over it, to read more about how it works.